Abstracts tagged "prognostic factors"

Abstract Number: 546 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression
Deepak R. Jadon¹, Gavin Shaddick², William Tillett¹, Graham Robinson³, Charlotte Cavill¹, Nicola Waldron¹, Eleanor Korendowych¹ and Neil J McHugh⁴, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Royal United Hospital, Bath, United Kingdom, ⁴Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Psoriatic arthritis mutilans (PAM) is a rare extreme subtype of psoriatic arthritis (PsA). Our objectives were to: (1) compare clinical characteristics of PsA patients…
Abstract Number: 395 • 2014 ACR/ARHP Annual Meeting
Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Rachel Audo¹, Claire I. Daien², Laura Papon¹, Cédric Lukas³, O Vittecoq⁴, B Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rouen University Hospital & Inserm U905, Rouen, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France
Background/Purpose : TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear…
Abstract Number: 2925 • 2014 ACR/ARHP Annual Meeting
Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy
Kazuko Shiozawa¹, Takashi Yamane², Miki Murata¹, Chihiro Tanaka¹, Noriaki Yo², Ryosuke Yoshihara¹, Yasushi Tanaka¹, Ken Tsumiyama³ and Shunichi Shiozawa⁴, ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Studies have shown that treating rheumatoid patients with methotrexate (MTX) monotherapy initially and later providing an option to step up to combination therapy produces…
Abstract Number: 2896 • 2013 ACR/ARHP Annual Meeting
Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Ian N. Bruce¹, Aidan O'Keefe², Li Su³, Vernon Farewell⁴, John G. Hanly⁵, Susan Manzi⁶, Murray B. Urowitz⁷ and Systemic Lupus International Collaborating Clinics (SLICC)⁸, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom, ²MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom, ³MRC Biostatistics Unit, Cambridge, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, ⁵Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Irreversible damage is an important outcome in patients with SLE. We aimed to study damage accrual in early SLE. We examined the rate of…
Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Nevsun Inanc^1,2, Gülsen Ozen² and Haner Direskeneli³, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…
Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Amir Haddad¹, Arane Thavaneswaran¹, Ioana Ruiz Arruza², Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…
Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Chisa Okura¹, Yukio Yonemoto², Koichi Okamura¹, Tetsuya Kaneko³, Tsutomu Kobayashi¹ and Kenji Takagishi¹, ¹Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, ³Department of Orthopaedic Surgery, Inoue Hospital, Takasaki, Gunma, Japan
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…
Abstract Number: 2335 • 2013 ACR/ARHP Annual Meeting
Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy
Heikki Valleala¹, Markku Korpela², Markku J. Kauppi³ and Yrjo T. Konttinen⁴, ¹Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ²Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴Dept of Medicine, Helsinki Univ Central Hospital, Helsinki, Finland
Background/Purpose: Autoreactive B-cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the aetiology of various human chronic autoimmune diseases. The aim of…
Abstract Number: 2260 • 2013 ACR/ARHP Annual Meeting
Smoking and Antibodies To Cyclic Citrullinated Peptides Predict Persistently High Levels Of Survivin In Early Rheumatoid Arthritis
Bjorn Svensson¹, Ingiäld Hafström², Malin Erlandsson³, Kristina Forslind⁴ and Maria Bokarewa³, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden, ³Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden
Background/Purpose: High levels of the oncoprotein survivin may be detected in the majority of patients with early rheumatoid arthritis (RA). Survivin is a sensitive predictor…
Abstract Number: 1537 • 2013 ACR/ARHP Annual Meeting
Primary & Subsequent Orthopedic Surgeries More Common In Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Deepak R. Jadon¹, Ramani Arumugam¹, Gavin Shaddick², Alison L Nightingale³, Athimalaipet V Ramanan⁴ and Raj Sengupta¹, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁴Paediatric Rheumatology, University of Bristol Hospital Trust, Bristol, United Kingdom
Background/Purpose: Patients experiencing ankylosing spondylitis (AS) symptoms ²16 years-of-age are classified as juvenile-onset AS (JoAS), whilst those ³17 years adult-onset AS (AoAS). We compared JoAS…
Abstract Number: 1441 • 2013 ACR/ARHP Annual Meeting
Predictive Factors Of Response To Tocilizumab In Patients With Active Rheumatoid Arthritis
Maria Victoria Hernández¹, Javier Narvaez², Raimon Sanmarti³, Delia Reina⁴, Cesar Diaz-Torne⁵, Berta Magallares⁵, Arturo Rodriguez de la Serna⁵, José María Llobet⁵, Hector Corominas⁴ and Joan Miquel Nolla², ¹Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: To analyze the efficacy and identify predictors of response to tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods: A multicenter ambispective observational study…
Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Cochin Hospital, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵APHP, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…
Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima¹, Yuichi Takahashi⁸, Seiyo Honda⁹, Yoshiro Horai², Tomohiro Koga¹⁰, Mami Tamai¹¹, Kiyoshi Aoyagi¹², Ryu Watanabe⁵, Hiroshi Okuno¹³ and Katsumi Eguchi¹⁴, ¹Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Yu Family Clinic, Sendai, Japan, ⁹Kurume University School of Medicene, Kurume, Japan, ¹⁰Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ¹²Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹³Tohoku University Hospital, Sendai, Japan, ¹⁴Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
Abstract Number: 878 • 2013 ACR/ARHP Annual Meeting
Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis
Anne Sofie Siebuhr¹, Anne C. Bay-Jensen¹, Diana J. Leeming², Adam Platt³, Inger Byrjalsen⁴, Claus Christiansen⁵, Désirée van de Heijde⁶ and Morten Asser Karsdal², ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁶Department of Rheumatology, Leiden Univerisity, Leiden, Netherlands
Background/Purpose: As biological treatments for rheumatoid arthritis (RA) are only effective in a subpopulation of patients and the treatment can have serious side effects, there…
Abstract Number: 695 • 2013 ACR/ARHP Annual Meeting
Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis
Nicolas Champtiaux¹, Vincent Cottin², Eric Hachulla³, Dominique Valeyre⁴, Hilario Nunes⁵, David Launay⁶, Alice Berezne⁷, Bruno Crestani⁸, Loic Guillevin⁹, Jean-Francois Cordier² and Luc Mouthon¹⁰, ¹Service de Médecine Interne, hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ³Internal Medicine, Lille CEDEX, France, ⁴Department of Pneumology, Avicenne hospital (APHP), Bobigny, France, ⁵Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁷Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁸Pneumology A, Hôpital Bichat, Paris, France, ⁹Internal Medicine, Cochin University Hospital, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis Background/Purpose: Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].